leisure time -WSS

leisure time

author：knowledge 2025-09-29 19:05:34 - browse：95665

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
Next article： Senate panel clears PBM, hopsital reforms

hotspot

knowledge

WSS

FDA approves Recor Medical high blood pressure device

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

Victims of gun violence feel impacts long after bullet wound

House GOP plan to stem drug shortages differs from Democrats’

5 wounded, 2 critically, in Michigan shopping center shooting

entertainment

leisure time

knowledge

Medical records are filled with copy

Trump PAC spent more than $40M on legal bills this year as his charges mount: Sources

Moonlake's readout produced a cash windfall. Risks remain

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

State Dept. review finds Biden bears some blame for Afghanistan failures

Poland's lawmakers approve a divisive law on Russian influence

At least 13 dead in Texas as scorching temps continue

FDA approves Recor Medical high blood pressure device

Medicare proposal to cover medical devices draws a mixed reaction

More doctors should go into startup world

focus

House GOP plan to stem drug shortages differs from Democrats’

Extreme heat events are a public health emergency

Medicare will require more price transparency from hospitals

Study: New antibiotic targets gonorrhea as well as last existing drug

Adidas to release second batch of Yeezy sneakers after breakup with Ye

The new shift in health care is toward less care

Wikipedia

hotspot

knowledge

focus